TENX TENAX THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 34956 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY0.4%
TTM EPS YoY-87.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-64.2%
ROA-59.8%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets7.1%
Debt / equity0.00x
Current ratio14.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | — | — | — |
| R&D expense | $32.67M | $12.71M | $3.23M | $5.38M | $25.15M |
| SG&A expense | $23.71M | $6.79M | $5.00M | $5.68M | $7.58M |
| Operating income | -$56.38M | -$19.49M | -$8.23M | $11.05M | -$32.73M |
| Interest expense | $0 | $23,000 | $24,000 | $4,443 | $949 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$52.60M | -$17.60M | -$7.71M | $11.05M | -$32.47M |
| EBITDA | — | -$19.49M | -$8.23M | $11.06M | -$32.72M |
| EPS (basic) | -1.34 | -1.15 | -31.04 | — | -1.58 |
| EPS (diluted) | -1.34 | -1.15 | -31.04 | — | -1.58 |
| Weighted avg. shares (diluted) | 39.22M | 15.27M | 248,447 | — | 20.58M |
| Banking | |||||
| Net interest income | — | — | — | — | $949 |
| Balance sheet | |||||
| Cash & equivalents | $97.56M | $94.85M | $9.79M | $2.12M | $5.58M |
| Short-term investments | — | — | — | — | $0 |
| Current assets | $104.23M | $96.69M | $11.68M | $3.21M | $5.69M |
| PP&E, net | — | — | $0 | $7,189 | $7,108 |
| Total assets | $104.23M | $96.69M | $11.69M | $3.40M | $5.99M |
| Current liabilities | $7.16M | $4.69M | $3.59M | $1.85M | $1.56M |
| Total liabilities | $7.16M | $4.69M | $3.59M | $1.91M | $1.75M |
| Shareholders' equity | $97.07M | $91.99M | $8.10M | $1.49M | $4.24M |
| Shares outstanding | 9.31M | 3.42M | 298,281 | 28,648 | 1.26M |
| Cash flow statement | |||||
| Operating cash flow | -$35.80M | -$14.81M | -$5.90M | -$11.39M | -$10.86M |
| Capital expenditure | — | — | — | $2,323 | $5,252 |
| Free cash flow | — | — | — | -$11.39M | -$10.86M |
| Investing cash flow | — | $0 | $3,000 | -$2,323 | $452,609 |
| Financing cash flow | $38.51M | $99.87M | $13.57M | $7.93M | $9.74M |
| Depreciation & amortization | — | $0 | $8,000 | $5,143 | $4,116 |
| Stock-based compensation | $19.16M | $1.12M | $191,000 | — | — |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.